Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | P2RX3 | P56373 | 3/20 | 0.64 |
| ▸ | P2RX4 | Q99571 | 3/20 | 0.64 |
| ▸ | P2RX2 | Q9UBL9 | 3/20 | 0.64 |
| ▸ | ENPP1 | P22413 | 1/20 | 0.59 |
| ▸ | GSK3A | P49840 | 2/20 | 0.59 |
| ▸ | RPS6KA3 | P51812 | 2/20 | 0.59 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.59 |
| ▸ | ABCB1 | P08183 | 1/20 | 0.57 |
| ▸ | P2RX1 | P51575 | 2/20 | 0.56 |
| ▸ | P2RX7 | Q99572 | 2/20 | 0.56 |
| ▸ | P2RX6 | O15547 | 1/20 | 0.56 |
| ▸ | P2RX5 | Q93086 | 1/20 | 0.56 |
| ▸ | P2RY11 | Q96G91 | 1/20 | 0.56 |
| ▸ | LMNA | P02545 | 1/20 | 0.53 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.51 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL9189337 | 0.92 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL12352429 | 0.92 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL12243789 | 0.92 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL13169185 | 0.92 | P2RX3 (0.75) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL5794949 | 0.90 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL532930 | 0.90 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL5983100 | 0.90 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL532929 | 0.90 | ENPP1 (0.71) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL532424 | 0.90 | P2RX3 (0.69) | P2RX3P2RX4P2RX2ENPP1GSK3A | |
| SCHEMBL12352420 | 0.90 | P2RX3 (0.69) | P2RX3P2RX4P2RX2ENPP1GSK3A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9290533-B2 | β-L-2′-deoxy-nucleosides for the treatment of hepatitis B | NOVARTIS AG (CH) | 2016-03-22 | — | — | US | disclosed |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2012-10-18 | — | — | US | disclosed |
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | IDENIX PHARMACEUTICALS, INC. (US) | 2011-10-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110257120-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
| US-20120264707-A1 | BETA-L-2'-DEOXY-NUCLEOSIDES FOR THE TREATMENT OF HEPATITIS B | PNP, DUT, ATIC | P2RX3 1266/4885P2RX4 1776/4885P2RX2 959/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.